Form 4: Emergent BioSolutions Director Neal Franklin Fowler Reports Acquisition and Disposal of Shares

Director Neal Franklin Fowler reports acquisition of 34,403 restricted stock units and 15,824 stock options, along with disposal of 135,503 common stock shares.

Summary

• On April 30, 2025, Neal Franklin Fowler, a director of Emergent BioSolutions Inc., reported transactions involving the company's stock.
• Fowler acquired 34,403 restricted stock units (RSUs) and 15,824 stock options as part of an annual grant for Board and Committee service.
• The RSUs will vest on the day prior to the one-year anniversary of the grant date, contingent on Fowler remaining a board member.
• Each RSU represents the right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• The stock options, with an exercise price of $5.45, also vest on the Annual Grant Vesting Date, subject to Fowler's continued board membership.
• The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
• Fowler also disposed of 135,503 common stock shares.
• Following these transactions, Fowler beneficially owns 135,503 shares of common stock and 41,572 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of RSUs and stock options to a director aligns their interests with the long-term performance of the company.
• The vesting requirements incentivize continued service on the board.

Negatives

• The disposal of 135,503 common stock shares by a director could be perceived negatively by investors, although the reason for disposal is not specified.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Emergent BioSolutions' stock.
• Changes in board membership could affect the vesting of the RSUs and stock options.

Future Outlook

The vesting of the RSUs and stock options is contingent on the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of company leadership.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the director's stock disposal.

Key Dates

Keywords

Emergent BioSolutions, Director, Form 4, Stock Options, RSUs, Beneficial Ownership, Securities, Transactions